Small molecule · Inhibitor of B-cell lymphoma-2 (BCL2) and Bcl-extra large (BCL2L1)
Phase 1Most advanced trial
1Registered trials
What is Nexatoclax?
Nexatoclax is an orally bioavailable inhibitor of the anti-apoptotic proteins Bcl-2 and Bcl-XL. It binds and inhibits these proteins to restore apoptotic processes in tumor cells. It is being studied in Philadelphia positive acute lymphoblastic leukemia.
Summary written with AI from the sources listed at the end of this page.
At a glance
Also known as
LP-118
Drug type
Small molecule
Targets
B-cell lymphoma-2 (BCL2), Bcl-extra large (BCL2L1)
Mechanism
Inhibitor of B-cell lymphoma-2 (BCL2) and Bcl-extra large (BCL2L1)
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.